{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-22-000033","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2022-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.319500+00:00","generated_at":"2026-06-23T04:08:49.095026+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition","bullets":["Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.","Board expanded from eight to nine directors; new Commercial Committee formed with Morrison, Yarno, Yeu-Lin, Crane (Chair).","Michael Ackermann expected to transition off Board by end of 2022; Bobak Azamian to become Chairperson, Wendy Yarno Lead Independent Director.","Morrison receives initial equity grant: option for 14,000 shares plus 4,000 RSUs.","Morrison is independent under Nasdaq standards and qualifies as audit committee financial expert."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-22-000033","json":"https://secwatch.observer/filing/0001819790-22-000033.json","markdown":"https://secwatch.observer/filing/0001819790-22-000033.md","text":"https://secwatch.observer/filing/0001819790-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/tars-20221006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:08:49.095026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25a00461d3","claim":"Scott Morrison was appointed as Director at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"62acf5cdb8","claim":"Bobak Azamian was appointed as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will be appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"c8f69de579","claim":"Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"will be appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"d1355aec1c","claim":"Michael Ackermann changed role as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"expected to transition off"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}